Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Anti-CLDN6 bispecific antibody** is a non-specific descriptor that can refer to multiple investigational antineoplastic biologics directed against **claudin 6**, most notably **CLDN6 x CD3 T-cell-engaging bispecific antibodies** such as CTIM-76, BNT142, and AMG 794. These agents are being developed for **CLDN6-positive solid tumors** including ovarian, endometrial, and testicular cancers. Their intended mechanism is to bind **CLDN6** on tumor cells and **CD3** on T cells, thereby redirecting T-cell cytotoxicity toward CLDN6-expressing cancer cells. Because the query does not identify a single molecule, developer, construct format, and development stage cannot be assigned to one unique drug with confidence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-CLDN6 bispecific antibody.